# A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Source: https://onco.cc/trials/nct05934513/  
OnCo record `nct05934513` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of GFH009 in peripheral T-cell lymphomas, run by Genfleet Therapeutics (Shanghai) Inc., now recruiting.

## Summary

A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) is a phase 1/2 interventional study registered as NCT05934513 by Genfleet Therapeutics (Shanghai) Inc., with 95 participants planned, started 2023-09-06 and due to reach its primary completion in 2025-12-30. Interventions recorded: GFH009.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05934513
- Phase: 1/2
- Setting: A Phase Ib/II, Multicentre, Open-label Study to Assess the Efficacy, Safety/ Tolerability and Pharmacokinetic of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
- Sponsor: Genfleet Therapeutics (Shanghai) Inc.
- Enrolled: 95

## Sources

- ClinicalTrials.gov NCT05934513: https://clinicaltrials.gov/study/NCT05934513

## Connected records

- cancers: [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/nct05934513.json